Dayspring, I think it was, considers palmitic acid as atherogenic.
Not sure if this is a remmnant of conventional wisdom or what.
Then I ran into this study. Probably worth looking into.
JCI - Palmitic acid mediates hypothalamic insulin resistance by altering PKC-? subcellular localization in rodents
Palmitic acid enhances lectin-like oxidized ... [Atherosclerosis. 2010] - PubMed - NCBI
Abstract
OBJECTIVE:
Elevated levels of nonesterified fatty acids (NEFA) in obesity and type 2 diabetes may contribute to the development of atherosclerosis. Therefore, we examined whether NEFA could regulate expression of scavenger receptors responsible for uptake of oxidized LDL (oxLDL) in macrophages, a critical step in atherogenesis.
METHODS AND RESULTS:
Expression level of scavenger receptors in NEFA-treated macrophage-like THP-1 and Raw264.7 cells were analyzed by real-time PCR. Palmitic acid showed the greatest enhancement of expression of lectin-like oxidized LDL receptor (LOX-1) among 7 NEFA examined (4 saturated and 3 unsaturated fatty acids). Upregulation of LOX-1 was selective as increases in expression level of other scavenger receptors (CD36, SR-AI, SR-BI, and CD68) were not observed. Western blotting analysis indicated that upregulation of LOX-1 also occurred at the protein level. Uptake of oxLDL by Raw264.7 cells was promoted by palmitic acid, and the enhanced uptake was abrogated when the cells were transfected with siRNA against LOX-1. Downregulation of Toll-like receptor (TLR) 2, TLR4, or IRAK4 with siRNA did not prevent LOX-1 upregulation, whereas inhibitors of p38 MAPK (p38) and reactive oxygen species (ROS) signal inhibited the upregulation of LOX-1 induced by palmitic acid.
CONCLUSIONS:
These results suggest that
elevated level of palmitic acid may contribute to development of atherosclerosis through enhanced uptake of oxLDL via upregulation of LOX-1 in macrophages. The effects of palmitic acid may be mediated by ROS-p38 pathway rather than TLRs.
Loren Cordain – Caution: Saturated Fats – Disaster with Grains | Me and My Diabetes
http://paleohacks.com/questions/56875/sat-fat-ldl-receptor-oops#axzz1uyyyAaeU
As consumption of certain saturated fatty acids (12:0, 14:0, 16:0, but not 18:0) increases, the number of hepatic (liver) and peripheral low-density lipoprotein (LDL) receptors decreases which in turn causes serum concentrations of LDL cholesterol to rise (a process called down regulation). Down regulation occurs because internalization of 12:0, 14:0 and 16:0 within cells reduces the expression of genes which code for the LDL receptor protein.
http://www.ajcn.org/content/73/2/198.full.pdf
Effect of 6 dietary fatty acids on the postprandial lipid profile, plasma fatty acids, lipoprotein lipase, and cholesterol ester transfer activities in healthy young men
http://apjcn.nhri.org.tw/server/apjcn/Volume11/vol11sup5/S433.pdf
Red palm oil in experimental atherosclerosis
The following findings provided a rationale for examining the effects of RPO in experimental atherosclerosis. Palm oil (PO) has been stigmatised as a hypercholesterolaemic fat because of its palmitic acid (16:0) content, despite human studies that show it does not raise serum cholesterol levels. 13,14
We have shown that the presence of palmitic acid at the SN2 position of a triglyceride renders that triglyceride more atherogenic.15–17 Cottonseed oil contains 24% palmitic acid but only 2% is at the SN2 position. Randomisation of cottonseed oil increases the amount of 16:0 at the SN2 position to 8.3% and trebles the severity of atherosclerosis.15 Lard and tallow both contain 20–24% palmitic acid. In lard, virtually all of the 16:0 is at the SN2 position and it is 113% more atherogenic than tallow. Randomisation of lard reduces the amount of 16:0 at the SN2 position by about 67% and reduces atherogenicity by 51%. Randomization of tallow increases the amount of 16:0 at the SN2 position by 124% and increases atherogenicity by 10%16 (Table 3). A study of synthetic triglycerides17 showed that 1,3-palmitoyl-2- oleoylglycerol was 53% less atherogenic than 1,2-palmitoyl- 3-oleoylglycerol.17